← Back to Search
Cytological Differential Diagnosis Among Adenocarcinoma, Epithelial Mesothelioma, And Reactive Mesothelial Cells In Serous Effusions By Immunocytochemistry
Xue-ying Su, G. Li, W. Liu, B. Xie, Yinghong Jiang
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
The objective of the study is to estimate the expression of some antibodies in the metastatic adenocarcinomas, malignant epithelial mesotheliomas, and reactive mesothelial cells in serous effusions and to choose effective panel to the differential diagnosis. Totally 113 effusion cytology samples (80 pleural fluid, 30 ascitic, and 3 pericardial fluid) from 60 cases of metastatic adenocarcinoma (ACA), 18 cases of malignant epithelial mesothelioma (MM), and 35 cases of reactive mesothelium (RM) were included in this study. The cytological diagnoses of these cases were confirmed by histopathology or clinical datas. Smears and cell blocks were prepared for each case. Immunocytochemical study was performed on the cell block sections. The sensitivity of E‐cadherin, CEA, MOC‐31, and Ber‐EP4 for adenocarcinoma was 86.7%, 80%, 70%, and 76.4%, respectively. The specificity was 98.1%, 96.2%, 92.5%, and 86.8%, respectively. The sensitivity of calretinin, HBME‐1, and thrombomodulin for RM/MM was 83%, 79.2%, and 47.2% respectively. The specificity was 88.3%, 21.7%, and 70%, respectively. The expression of E‐cadherin, CEA, MOC‐31, Ber‐EP4, calretinin, and thrombomodulin showed significant difference between ACA and RM/MM (P < 0.01). The reactivity of EMA and Des showed significant difference between RM and MM (P < 0.01). In our opinion, the antibody panel that consists of E‐cadherin, CEA, calretinin, and thrombomodulin should be the best for differential diagnosis between metastatic adenocarcinomas and RM/MM in serous effusions. EMA and Des should be used to differentiate malignant epithelial mesothelioma and reactive mesothelial cells. EMA positive and Des negative favor MM, while Des positive and EMA negative favor RM. Diagn. Cytopathol. 2011.
This paper references
A useful antibody panel for differential diagnosis between peritoneal mesothelioma and ovarian serous carcinoma in Japanese cases.
Y. Takeshima (2008)
E-cadherin and Cytokeratin Subtype Profiling in Effusion Cytology
J. Han (2004)
Monoclonal mouse anti-human epithelial antigen, clone Ber-EP4 package insert. CA: Dako corporation
Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens
Noriko Kimura (2009)
Immunocytochemistry in effusion cytology
P. Fetsch (2001)
Differentiating reactive mesothelial cells from metastatic adenocarcinoma in serous effusions: The utility of immunocytochemical panel in the differential diagnosis
H. Saleh (2009)
Calretinin staining pattern
DC Chhieng (1998)
Cell contacts, differentiation, and invasiveness of epithelial cells.
J. Behrens (1994)
Value of Mesothelin Immunostaining in the Diagnosis of Mesothelioma
N. Ordóñez (2003)
Thyroid transcription factor‐1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins A and B
The use of immunohistochemistry to distinguish reactive mesothelial cells from malignant mesothelioma in cytologic effusions
F. Hasteh (2010)
WT1, monoclonal CEA, TTF1, and CA125 antibodies in the differential diagnosis of lung, breast, and ovarian adenocarcinomas in serous effusions
Weijian Zhu (2007)
MOC - 31
Podoplanin is a useful marker for identifying mesothelioma in malignant effusions
Atef N Hanna (2010)
Use of mesothelin as a marker for mesothelial cells in cytologic specimens.
Cornelius Kachali (2006)
HBME‐1, MOC‐31, WT1 and calretinin: an assessment of recently described markers for mesothelioma and adenocarcinoma
Usefulness of EMA, GLUT-1, and XIAP for the cytologic diagnosis of malignant mesothelioma in body cavity fluids.
J. Shen (2009)
The art & science of cytopathology
R. Demay (1996)
In search of a positive immunohistochemical marker for mesothelioma: an update.
N. Ordóñez (1998)
Cytologic malignancy versus benignancy: how useful are the "newer" markers in body fluid cytology?
Virganeyce Lyons-Boudreaux (2008)
Evaluation of 12 antibodies for distinguishing epithelioid mesothelioma from adenocarcinoma: identification of a three-antibody immunohistochemical panel with maximal sensitivity and specificity
H. Yaziji (2006)
E‐cadherin, N‐cadherin, and calretinin in pleural effusions: The good, the bad, the worthless
A. Simsir (1999)
Immunocytochemistry in the differential diagnosis of serous effusions
M. Lozano (2001)
Role of immunohistochemistry in differentiating epithelial mesothelioma from adenocarcinoma. Review and update.
N. Ordóñez (1999)
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
N. Ordóñez (1998)
The Immunohistochemical Diagnosis of Mesothelioma: Differentiation of Mesothelioma and Lung Adenocarcinoma
N. Ordóñez (1989)
Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis
E. Çakır (2009)
MOC‐31 aids in the differentiation between adenocarcinoma and reactive mesothelial cells
R. Morgan (1999)
Role of immunohistochemisty in differentiating epithelial mesothelioma from adenocarcinoma
NG Ordonez (1999)
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions
P. Shield (2008)
E‐cadherin expression is a sensitive and specific method for detection of carcinoma cells in fluid specimens
K. Schofield (2000)
Utility of the antibodies CA 19‐9, HBME‐1, and thrombomodulin in the diagnosis of malignant mesothelioma and adenocarcinoma in cytology
P. Fetsch (1998)
The diagnostic utility of D2‐40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement
R. Saad (2006)
Immunoperoxidase staining on frozen tissue sections as a first screening assay in the preparation of monoclonal antibodies directed against small cell carcinoma of the lung.
L. de Leij (1984)
Calretinin staining pattern aids in the differentiation of mesothelioma from adenocarcinoma in serous effusions
D. Chhieng (2000)
This paper is referenced by
Expression and significance of MOC‐31 and calretinin in pleural fluid of patients with lung cancer
M. Lv (2015)
Utility of MOC-31 monoclonal antibody in differentiating metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cytology
B. Patil (2018)
[Value of Cell Block in the Diagnosis of Malignant Pleural Effusion].
Fangyuan Cheng (2015)
Diagnostic utility of cell blocks and an immunomarker panel in the cytological evaluation of serous effusions
Hanan Yehia Tayel (2019)
Diagnostic Usefulness of Claudin-3 and Claudin-4 for Immunocytochemical Differentiation between Metastatic Adenocarcinoma Cells and Reactive Mesothelial Cells in Effusion Cell Blocks
N. I. Kim (2016)
The application of immunocytochemistry to direct smears in the diagnosis of effusions
Stewart M Knoepp (2013)
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers
D. Henderson (2013)
Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.
Daniel E Schwed Lustgarten (2013)
Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
Nosheen Khurram (2019)
Epithelial cell adhesion molecule (MOC31) antibody expression in salivary gland tumors and squamous cell carcinoma
Yaser Ahmed (2015)
Ancillary studies in pleural, pericardial, and peritoneal effusion cytology
K. Sundling (2018)
Immunocytochemistry: an indispensable technique in routine cytology
L. Skoog (2011)
Ber-EP4 staining in effusion cytology: A potential source of false positives
C. Arco (2020)
A 2‐year retrospective study on pleural effusions: A cancer centre experience
E. Valerio (2019)
Diagnostic molecular biomarkers for malignant pleural effusions.
K. Sriram (2011)
Cytologic Differential Diagnosis of Malignant Mesothelioma and Reactive Mesothelial Cells With FISH Analysis of p16
K. Hiroshima (2016)
EZH2, a unique marker of malignancy in effusion cytology
Huimiao Jiang (2014)
Characterization of a new mouse model of empyema and the mechanisms of pleural invasion by Streptococcus pneumoniae.
S. Wilkosz (2012)
Lung cancer coexisting with ipsilateral pleural effusion
F. Rodríguez-Panadero (2014)
反応性中皮細胞との鑑別に苦慮した扁平上皮への分化を伴う子宮体部類内膜腺癌の腹腔洗浄細胞診の 1 例
高瀬 頼妃呼 (2014)
The role of liquid‐based cytology and ancillary techniques in pleural and pericardic effusions: An institutional experience
E. Rossi (2015)
Comparison of the diagnostic accuracy of cell block with cytology smear in serous effusions
P. Bista (2013)
Immunocytochemical utility of claudin‐4 versus those of Ber‐EP4 and MOC‐31 in effusion cytology
T. Oda (2016)
Diagnostic Accuracy of Calretinin for Malignant Mesothelioma in Serous Effusions: a Meta-analysis
Diandian Li (2015)
Immunocytochemical expression of a panel of markers in pleural effusions from patients with primary lung adenocarcinoma.
Eleftheria Chaini (2017)
Diagnostic Accuracy of Ber-EP4 for Metastatic Adenocarcinoma in Serous Effusions: A Meta-Analysis
B. Wang (2014)
The Role of Immunohistochemistry Studies in Distinguishing Malignant Mesothelioma from Metastatic Lung Carcinoma in Malignant Pleural Effusion
Monireh Halimi (2019)
Malignant pericardial mesothelioma
S. Cao (2016)
Diagnostic Accuracy of Epithelial Membrane Antigen for Malignant Effusions: A Meta-Analysis
Wentao Lin (2016)
Monoclonal Caveolin 1 Expression in the Differential Diagnosis of Malignant Pleural Mesothelioma and Pulmonary Adenocarcinoma: Is it Useful?
Zehra Bozdağ (2019)
Diagnostic accuracy of E-cadherin for malignanteffusions: a systematic review and meta-analysis
Fangying Chen (2020)
A new cancer cell detection method using an infectivity-enhanced adenoviral vector.
J. Uchino (2012)See more